Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M5,932Revenue $M287Net Margin (%)-27.1Altman Z-Score13.5
Enterprise Value $M5,636EPS $-0.6Operating Margin %-27.5Piotroski F-Score3
P/E(ttm)--Beneish M-Score-2.6Pre-tax Margin (%)-27.1Higher ROA y-yN
Price/Book27.410-y EBITDA Growth Rate %-4.9Quick Ratio2.8Cash flow > EarningsY
Price/Sales19.05-y EBITDA Growth Rate %-12.7Current Ratio3.1Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-17.5Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-37.0Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M125ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with SGEN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SGENFirst Eagle Investment 2010-03-31 Sold Out -0.01%$9.34 - $12.59
($10.84)
$ 47.50338%Sold Out0
SGENFirst Eagle Investment 2009-12-31 Buy 0.01%$8.74 - $13.16
($9.69)
$ 47.50390%New holding67,373
SGENBill Gates 2009-09-30 Sold Out -0.39%$8.75 - $14.8
($11.69)
$ 47.50306%Sold Out0
SGENFirst Eagle Investment 2009-06-30 Sold Out -0.01%$8.18 - $10.34
($9.08)
$ 47.50423%Sold Out0
SGENFirst Eagle Investment 2009-03-31 Add$7.23 - $10.36
($9.4)
$ 47.50405%Add 40.00%70,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SGEN is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


SGEN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
SIEGALL CLAY BPresident and CEO 2015-07-06Sell3,718$46.941.19 view
SIEGALL CLAY BPresident and CEO 2015-06-03Sell3,718$45.723.89 view
BAKER FELIXDirector, 10% Owner 2015-05-21Buy950,886$42.4911.79 view
DOBMEIER ERICCOO 2015-05-08Sell17,074$40.3817.63 view
SIEGALL CLAY BPresident and CEO 2015-05-08Sell52,052$40.6516.85 view
BAKER FELIXDirector, 10% Owner 2015-05-07Buy1,032,664$35.5633.58 view
Cline Darren SSVP, Commercial 2015-03-13Sell7,500$38.6522.9 view
HIMES VAUGHN BEVP, Proc Svcs & Tech Ops 2015-03-12Sell20,000$36.6529.6 view
BAKER FELIXDirector, 10% Owner 2015-03-10Buy285,036$34.6637.05 view
BAKER FELIXDirector, 10% Owner 2015-03-04Buy448,841$34.8436.34 view

Quarterly/Annual Reports about SGEN:

    News about SGEN:

    Articles On GuruFocus.com
    Insiders keep on buying Macerich Co and Seattle Genetics May 22 2015 
    Insiders new buys : ZU, SGEN, MAC, SHLD, TBRA May 12 2015 
    Seattle Genetics: Can Record Growth From Its Licenses Oct 28 2014 
    Seattle Genetics: Can Record Sustained Growth From Royalty Aug 31 2014 
    Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
    Weekly CFO Sells Highlight: USB, SGEN, CAH, ALXN, ABMD Jul 21 2013 
    Comment for Companies Ranked by Business Predictability Jan 03 2013 
    Weekly CFO Sells Highlight: SGEN, PFIE, MAR, ESRX, LIOX, RGEN Sep 10 2012 
    WEEKLY CFO SELLS HIGHLIGHT: SBAC, XOXO, MTH, FICO, SGEN, OAS Sep 03 2012 
    Weekly CFO Sells Highlight: SWKS, P, SGEN, RT Jun 11 2012 

    More From Other Websites
    Cramer: Receptos perfect fit for Celgene Jul 15 2015
    Synageva Biopharma Corp (GEVA) Acquisition Helps Baker Bros. Advisors Top All Others In Q2 Returns Jul 10 2015
    Growing Seattle Genetics tests cancer therapy for treatment of lupus Jul 09 2015
    Seattle Genetics Initiates Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Systemic Lupus... Jul 09 2015
    Seattle Genetics Initiates Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Systemic Lupus... Jul 09 2015
    Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2015 Financial... Jul 08 2015
    Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2015 Financial... Jul 08 2015
    WEEKEND VIDEO: Sentiment, Stocks and more Jul 03 2015
    Edited Transcript of SGEN earnings conference call or presentation 30-Apr-15 8:30pm GMT Jun 30 2015
    Collaborations make Seattle Genetics a safer way to play biotech Jun 24 2015
    SEATTLE GENETICS INC /WA Files SEC form 8-K, Change in Directors or Principal Officers Jun 22 2015
    Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at the... Jun 17 2015
    Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at the... Jun 17 2015
    The Zacks Analyst Blog Highlights: Regeneron, Vertex, Celgene, Seattle Genetics and SAGE... Jun 11 2015
    Biotech Stock Roundup: FDA Panel Recommends Regeneron's Praluent, SAGE Gains on Data - Analyst Blog Jun 10 2015
    A cancer cure that excites investors: A look at Seattle's immunotherapy deals of 2015 Jun 09 2015
    Seattle Genetics-Unum Therapeutics Tie Up for Cancer Drugs - Analyst Blog Jun 09 2015
    Seattle Genetics pays Boston-area company $25M to grow immunotherapy portfolio Jun 09 2015
    Seattle Genetics and Unum Therapeutics Enter into Strategic Cancer Immunotherapy Collaboration Jun 08 2015
    Seattle Genetics and Unum Therapeutics Enter into Strategic Cancer Immunotherapy Collaboration Jun 08 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK